As depicted in Figure 2, significantly higher proportions of CD4+CD25-Foxp3+ T cells were observed in SLE patients who were treated with cyclophosphamide (11.5 ± 0.3%) as compared to patients with other treatment regimes (4.3 ± 0.4%; P = 0.0001). Here, FOXP3 is linked to systemic lupus erythematosus.